Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04318145 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate Sex Differences in the Acute Effects of PL-3994 in Heart Failure Subjects
A Phase 2 study, sponsored by Palatin Technologies.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT04318145 is a Phase 2 study that was terminated before completion, run by Palatin Technologies. The registered enrollment target is 15 participants.
The verdict
NCT04318145, a Phase 2 study, was terminated before completion, sponsored by Palatin Technologies.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
A Multi-Center, Unblinded, Single-Arm Study to Evaluate Sex Differences in the Acute Effects of PL-3994 on Myocardial cGMP Enhancement and Hemodynamics in Heart Failure with Preserved Ejection Fraction
Interventions
- DRUG PL-3994 Aqueous Intravenous Solution Dose Ascention
- DRUG PL-3994 Aqueous Intravenous Solution Single Dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2020-11-12 |
| Est. Completion | 2023-12-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04318145
The ClinicalTrials.gov registry entry for NCT04318145 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Palatin Technologies, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PL-3994 Aqueous Intravenous Solution Dose Ascention is the first listed.
NCT04318145 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04318145 about?
NCT04318145 is a clinical study titled "Study to Evaluate Sex Differences in the Acute Effects of PL-3994 in Heart Failure Subjects". A Multi-Center, Unblinded, Single-Arm Study to Evaluate Sex Differences in the Acute Effects of PL-3994 on Myocardial cGMP Enhancement and Hemodynamics in Heart Failure with Preserved Ejection Fraction
What is the current status of trial NCT04318145?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2020-11-12. Estimated completion is 2023-12-08.
What interventions are being tested in trial NCT04318145?
The interventions under investigation include: PL-3994 Aqueous Intravenous Solution Dose Ascention (DRUG), PL-3994 Aqueous Intravenous Solution Single Dose (DRUG).
Who is sponsoring clinical trial NCT04318145?
This trial is sponsored by Palatin Technologies, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.